臨床外科75巻13号

2020年12月発行

FOCUS

胆道癌薬物療法の最新動向

著者： 岡野尚弘¹ 廣田玲¹ 西岡真理子¹ 杉浦ちとせ¹ 前園知宏¹ 河合桐男¹ 水谷友紀¹ 長島文夫¹ 古瀬純司¹

所属機関： ¹杏林大学医学部腫瘍内科学

ページ範囲：P.1484 - P.1488

はじめに
　胆道癌は乳頭部を含む肝外胆道系に原発したがん腫であり，「胆道癌取扱い規約」により肝外胆管癌，胆囊癌，十二指腸乳頭部癌に分類される．肝内胆管癌は，取扱い規約では原発性肝癌として取り扱われているが，治療開発は胆道癌として進められている．胆道癌では，外科手術のみが根治を期待できる治療法であるが，切除例の6〜7割に再発が認められ，切除例でさえ予後不良な難治癌である．胆道癌全体の予後改善には，切除不能例や術後再発例に対する化学療法，根治切除例に対する術後補助化学療法の開発が必須である．
　近年，切除不能・再発胆道癌に対する一次治療の二つの第Ⅲ相試験の結果が本邦から発表された．二次治療においては海外から有望な治療薬の結果が相次いで発表されている．また，術後補助化学療法に関しても，本邦で実施されている第Ⅲ相試験の結果がまもなく公表される予定であり，期待が高まっている．

参考文献

1）Eckel F, Schmid RM：Chemotherapy in advanced biliary tract carcinoma：a pooled analysis of clinical trials. Br J Cancer 96：896-902, 2007

2）Valle JW, Wasan H, Johnson P, et al：Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours：a multicentre randomised phase Ⅱ study-The UK ABC-01 Study. Br J Cancer 101：621-627, 2009

3）Valle J, Wasan H, Palmer DH, et al：Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362：1273-1281, 2010

4）Okusaka T, Nakachi K, Fukutomi A, et al：Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer：a comparative multicentre study in Japan. Br J Cancer 103：469-474, 2010

5）Valle JW, Furuse J, Jitlal M, et al：Cisplatin and gemcitabine for advanced biliary tract cancer：a meta-analysis of two randomised trials. Ann Oncol 25：391-398, 2014

6）Morizane C, Okusaka T, Mizusawa J, et al：Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer：the FUGA-BT（JCOG1113）randomized phase Ⅲ clinical trial. Ann Oncol 30：1950-1958, 2019

7）Sakai D, Kanai M, Kobayashi S, et al：Randomized phase Ⅲ study of gemicitabine, cisplatin plus S-1（GCS）versus gemcitabine, cisplatin（GC）for advanced biliary tract cancer（KHBO1401-MITSUBA）. Ann Oncol 29（suppl_8）：Abstract 1405, 2018

8）Suzuki E, Ikeda M, Okusaka T, et al：A multicenter phase Ⅱ study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71：1141-1146, 2013

9）Sasaki T, Isayama H, Nakai Y, et al：Multicenter phase Ⅱ study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30：708-713, 2012

10）Okano N, Kasuga A, Kawai K, et al：The modified glasgow prognostic score in patients with gemcitabine-refractory biliary tract cancer. Anticancer Res 38：1755-1761, 2018

11）Lamarca A, Palmer DH, Wasan HS, et al：ABC-06｜a randomised phase Ⅲ, multi-Centre, open-label study of active symptom control（ASC）alone or ASC with oxaliplatin/5-FU chemotherapy（ASC＋mFOLFOX）for patients（pts）with locally advanced/metastatic biliary tract cancers（ABC）previously-treated with cisplatin/gemcitabine（CisGem）chemotherapy. J Clin Oncol 37：4003（abstract）, 2019

12）Abou-Alfa GK, Macarulla T, Javle MM, et al：Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma（ClarIDHy）：a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21：796-807, 2020

13）Javle M, Lowery M, Shroff RT, et al：Phase Ⅱ Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 36：276-282, 2018

14）Abou-Alfa GK, Sahai V, Hollebecque A, et al：Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma：a multicentre, open-label, phase 2 study. Lancet Oncol 21：671-684, 2020

15）Ueno M, Ikeda M, Morizane C, et al：Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer：a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 4：611-621, 2019

16）Kim RD, Chung V, Alese OB, et al：A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol 6：1-8, 2020

17）Piha-Paul SA, Oh DY, Ueno M, et al：Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer：Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer, 2020［Online ahead of print］

18）Neoptolemos JP, Moore MJ, Cox TF, et al：Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma：the ESPAC-3 periampullary cancer randomized trial. Jama 308：147-156, 2012

19）Ebata T, Hirano S, Konishi M, et al：Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105：192-202, 2018

20）Edeline J, Benabdelghani M, Bertaut A, et al：Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer（PRODIGE 12-ACCORD 18-UNICANCER GI）：A Randomized Phase Ⅲ Study. J Clin Oncol 37：658-667, 2019

21）Primrose JN, Fox RP, Palmer DH, et al：Capecitabine compared with observation in resected biliary tract cancer（BILCAP）：a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20：663-673, 2019